MgSO4 Protocol for Fetal Neuroprotection in Preterm Delivery <32 Weeks
Administer magnesium sulfate for fetal neuroprotection when delivery is anticipated before 32 weeks gestation, using a 4 g IV loading dose over 20-30 minutes followed by 1 g/hour maintenance infusion until delivery or for a maximum of 12-24 hours. 1, 2
Indications and Timing
Gestational Age Criteria:
- Strongly recommended: <32 weeks gestation 1, 2
- Consider: Up to 32-34 weeks gestation 2
- Administer regardless of cause of preterm birth (preeclampsia, PPROM, preterm labor, fetal growth restriction) 1, 2
- Use for both singleton and multiple pregnancies 2, 3
Timing of Administration:
- Give when delivery is planned or expected within 24 hours 2
- Ideally commence as close as possible to 4 hours before birth 2
- Critical point: If delivery expected sooner than 4 hours, still administer—there is benefit even with shorter exposure 2
Dosing Protocol
Loading Dose:
- 4 g magnesium sulfate IV over 20-30 minutes 4, 2, 3
- Dilute 50% solution to 20% or less concentration before IV administration 4
- Can use 4 g in 250 mL of 5% dextrose or 0.9% normal saline 4
Maintenance Dose:
- 1 g/hour IV infusion 2, 3
- Continue until delivery 2
- Maximum duration: 12-24 hours if undelivered 2, 3
- Do not exceed: 50 g cumulative dose 3
Alternative regimen (from FDA label for eclampsia, though neuroprotection uses lower doses): Initial 4-5 g IV, then 4-5 g IM every 4 hours as needed 4—however, the continuous infusion protocol above is preferred for neuroprotection 2, 3
Monitoring Requirements
During Infusion (every 4 hours minimum): 2
- Pulse
- Blood pressure
- Respiratory rate (maintain ≥16 breaths/min) 4
- Deep tendon reflexes (patellar reflex) 4, 2
Safety Parameters:
- Urine output should be ≥100 mL in 4 hours preceding each dose 4
- Stop infusion if: Absent patellar reflexes, respiratory rate <16/min, or urine output inadequate 4
- Target therapeutic serum magnesium: 2.0-3.5 mmol/L (approximately 5-8 mg/dL) 2, 5
Have calcium gluconate immediately available to reverse magnesium toxicity if needed 4
Evidence for Neuroprotection
The evidence strongly supports this practice:
- Reduces cerebral palsy by 29% (RR 0.71,95% CI 0.57-0.89) 6
- Reduces death or cerebral palsy by 13% (RR 0.87,95% CI 0.77-0.98) 6
- Reduces severe intraventricular hemorrhage 6, 7
- Reduces moderate-severe white matter injury (adjusted OR 0.208) 7
- Improves motor and cognitive outcomes at 36 months 7
The most recent Cochrane review (2024) provides high-certainty evidence for these benefits 6.
Critical Contraindications and Warnings
Do NOT use for prolonged tocolysis: The FDA explicitly warns against continuous administration beyond 5-7 days, which can cause fetal hypocalcemia, skeletal demineralization, osteopenia, and neonatal fractures 4, 8. However, short-term use (<48 hours) for neuroprotection is safe and recommended 8.
Renal impairment: Use with extreme caution; maximum 20 g/48 hours with frequent serum magnesium monitoring 4
Maternal side effects: Magnesium increases adverse effects severe enough to stop treatment (RR 3.21), though serious maternal complications are rare 6. Common effects include flushing, warmth, nausea.
Key Distinctions
This protocol differs from MgSO4 use for eclampsia prophylaxis, which uses higher total doses (10-14 g initial, then 4-5 g IM every 4 hours or 1-2 g/hour continuous infusion for 24 hours postpartum) 1, 4. For neuroprotection, the lower dose (4 g load + 1 g/hour maintenance) is appropriate and evidence-based 2, 3, 6.
The neuroprotective benefit is primarily demonstrated before 30-32 weeks gestation 9, 6, with the strongest evidence in the 23-27 week subgroup 10.